This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Analysis of effectiveness
The analysis of the clinical study was based on both intention to treat and treatment completers only (per-protocol analysis). The main primary outcome was hospitalisation time with GM-CSF or placebo, (which leads to the period of resolution of neutropenia (>1.0x10?9/L) and fever (temperature < 37.5 degrees C)) in conjunction with quality of life (six dimensions: mobility, emotional reactions, energy, social isolation, pain, sleep). The instruments used to valuate the quality of life score in both treatment groups were the Karnofsky performance index (generic instrument), the Nottingham Health profile (generic instrument), the Rotterdam Symptom Checklist (cancer-specific instrument) and the EuroQoL (valuation instrument, patient and population scores). The mortality rates were also reported. The groups were shown to be comparable in terms of age, sex, tumour type, and neutrophil count. The effects of confounding variables were assessed by analysing the risk of hospitalisation in a Cox proportional regression model (adjusted risk reductions were calculated).
Effectiveness results
In the GM-CSF group, according to an intention-to treat analysis, the number of days of hospitalisation was 6 (range: 3 -14) as opposed to 7 (range: 3 -14) days in the placebo group, (p=0.27). At day 4, the GM-CSF group had a median neutrophil count of 2.5 x 10?9/L (range: 0 -25) versus 1.3 x10?9/L (range: 0 -9) in the placebo group, (p<0.001). No significant differences were observed in time to resolution of fever (days): 3 days (range: 1 -14) for both GM-CSF and placebo arms. The scores for the Karnofsky performance index were greater for the GM-CSF than for the placebo group (74 versus 63), (p=0.034). Patients in the placebo group showed less complaints than patients receiving GM-CSF treatment. The GM-CSF arm had a more pronounced health-related quality of life dimension than the placebo group in terms of mobility, emotional, and energy problems. No significant differences were noticed in the EuroQoL scores taking into account patient values. The patient value was better for the placebo arm than for the GM-CSF group (66 versus 54) as was the population score (57 versus 55). The Rotterdam Symptom Checklist demonstrated that patients in the placebo group experienced fewer problems concerning appetite and energy than patients in the GM-CSF group, (p<0.01). No differences were shown in terms of tiredness, dry mouth or sweating. The adjusted risk reduction for the number of days of hospitalisation was 29%, (p=0.12). The mortality was 1 patient in the GM-CSF group versus 2 patients in the control group (NS).
Clinical conclusions
In three previous studies, a significant advantage was observed for GM-CSF or G-CSF treatment. In the present study, only a trend toward an advantage for GM-CSF application was seen. The difference might be ascribed to differences in patient categories and treatment protocols.
Measure of benefits used in the economic analysis
No summary benefit measure was identified in the economic analysis, and only separate clinical outcomes were reported.
Direct costs
Costs were not discounted due to the short follow-up period. Quantities were not reported separately from the costs. The cost items were reported separately. The cost analysis covered the costs of hospital, consultations, laboratory services, diagnostic (including imaging) procedures, antibiotics, and GM-CSF. Hospital costs included the costs of manpower (doctors, nurses, etc), materials (medical devices, supportive patient care, etc), and overhead. The perspective adopted in the cost analysis was not explicitly specified. The resource use data were gathered from all registry forms and from daily data forms. The sources of cost data were different national and local organisations. The price data referred to 1992.
